Tryn Stimart - Jun 7, 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Legal Officer
Signature: /s/ Tryn Stimart
Stock symbol: ABCL
Transactions as of: Jun 7, 2021
Transactions value $: $815,000
Form type: 4
Date filed: 6/9/2021, 08:30 PM
Next filing: Jun 10, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABCL	Common Shares	Options Exercise	$240K	+750K	+300000%	$0.32^*	750K	Jun 7, 2021	Direct
transaction	ABCL	Common Shares	Options Exercise	$575K	+250K	+33.32%	$2.30	1M	Jun 7, 2021	Direct
holding	ABCL	Common Shares						250	Jun 7, 2021	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share Option (right to buy)	Options Exercise	$0	-750K	-37.5%	$0.00	1.25M	Jun 7, 2021	Common Shares	750K	$0.32	Direct	F1, F2
transaction	ABCL	Share Option (right to buy)	Options Exercise	$0	-250K	-29.41%	$0.00	600K	Jun 7, 2021	Common Shares	250K	$2.30	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Previously reported on Form 3 filed on December 11, 2020. The vesting schedule was amended as follow: 25% of the shares subject to such option vest and become exercisable on August 22, 2020; 6.25% of the shares subject to such option vest and become exercisable on November 22, 2020 and February 22, 2021; 4.70% of the shares subject to such option vest and become exercisable on on July 1, 2022; 8.9% of the shares subject to such option vest and become exercisable on October 1, 2022; 7.4% of the shares subject to such option vest and become exercisable on January 1, 2023; 10.40% of the shares subject to such option vest and become exercisable on April 1, 2023; 8.90% of the shares subject to such option vest and become exercisable on July 1, 2023 and October 1, 2023; 2.70% of the shares subject to such option vest and become exercisable on January 1, 2024;
F2	(Continued from footnote 1) and 2.65% of the shares subject to such option vest and become exercisable on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025.
F3	Previously reported on Form 3 filed on December 11, 2020 and Form 4 filed on December 17, 2020. The vesting schedule was amended such that all of the shares subject to such option were vested as of March 24, 2021.